Literature summary for 1.14.11.27 extracted from

Staberg, M.; Rasmussen, R.D.; Michaelsen, S.R.; Pedersen, H.; Jensen, K.E.; Villingshoj, M.; Skjoth-Rasmussen, J.; Brennum, J.; Vitting-Seerup, K.; Poulsen, H.S.; Hamerlik, P.
Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B (2018), Mol. Oncol., 12, 406-420 .

Search for more literature for 1.14.11.27

Application

Application	Comment	Organism
medicine	JmjC domain histone H3K36me2/me1 demethylase KDM2B is highly expressed in glioblastoma surgical specimens compared to normal brain. Targeting KDM2B function genetically or pharmacologically impairs the survival of patient-derived primary glioblastoma cells through the induction of DNA damage and apoptosis and sensitizes them to chemotherapy. KDM2B loss decreases the cancer stem-like cells pool, which is potentiated by coadministration of chemotherapy	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	Q8NHM5	-	-

Synonyms

Synonyms	Comment	Organism
KDM2B	-	Homo sapiens

General Information

General Information	Comment	Organism
physiological function	JmjC domain histone H3K36me2/me1 demethylase KDM2B is highly expressed in glioblastoma surgical specimens compared to normal brain. Targeting KDM2B function genetically or pharmacologically impairs the survival of patient-derived primary glioblastoma cells through the induction of DNA damage and apoptosis and sensitizes them to chemotherapy. KDM2B loss decreases the cancer stem-like cells pool, which is potentiated by coadministration of chemotherapy	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)